~~<i id='804277C9B6'><strike id='804277C9B6'><tt id='804277C9B6'><pre id='804277C9B6'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：focus 2025-09-28 10:08:40 Page View：73

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Study: Hearing aids may slow cognitive decline in those at risk
Next article： Alkermes shareholders re

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

IsraelisblockahighwayastheyprotestagainstplansbyPrimeMinisterBenjaminNetanyahu'sgovernmenttooverhaul

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

1:35VIDEO:Catchuponthedevelopingstoriesmakingheadlines.STOCKIMAGE/GettyImagesAFordassemblyplantinCla

WSS

focus

focus

leisure time

explore

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says